Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 3/2019

01-06-2019 | Case Report

Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria

Authors: Herbert Hof, C. Juretschke

Published in: Infection | Issue 3/2019

Login to get access

Abstract

The number of multi-resistant uropathogens is increasing. A multi-morbid patient developed a symptomatic urinary tract infection with two multi-resistant bacteria, namely Klebsiella pneumoniae and Proteus mirabilis. Nitroxoline was the only drug active against both uropathogens. Obviously, nitroxoline can be an option for the therapy of a urinary tract infection with multi-resistant uropathogens.
Literature
1.
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 update of the german clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int. 2018;100:271–8.CrossRefPubMed
2.
Hof H, Bertsch D, Passek D, Schwarz R. Nitroxolin—eine Option zur antibiotischen Therapie von Harnwegsinfektionen. Der Urol. 2017;56:167–71.CrossRef
3.
Hof H. Candidurie! Was nun? Zur Therapie von Harnwegsinfektionen durch Candida. Der Urol. 2017;56:172–9.CrossRef
4.
Wagenlehner FM, Münch F, Pilatz A, Bärmann B, Weidner W, Wagenlehner CM, Straubinger M, Blenk H, Pfister W, Kresken M, Naber KG. Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. Antimicrob Agents Chemother. 2014;58:713–21.CrossRefPubMedPubMedCentral
5.
Naber KG, Niggemann H, Stein G, Stein G. Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. BMC Infect Dis. 2014;14:628.CrossRefPubMedPubMedCentral
6.
Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant gram-negative bacteria. J Antimicrob Chemother. 2010;65:iii25–33.CrossRefPubMed
7.
Cek M, Tandoğdu Z, Wagenlehner F, Tenke P, Naber K, Bjerklund-Johansen TE. Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010. World J Urol. 2014;32:1587–94.CrossRefPubMed
8.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.CrossRefPubMedPubMedCentral
9.
Arana DM, Rubio M, Alós JI. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: a 12-year analysis (2003–2014). Enferm Infecc Microbiol Clin. 2017;35:293–8.CrossRefPubMed
10.
Esteve-Palau E, Grau S, Herrera S, Sorlí L, Montero M, Segura C, Durán X, Horcajada JP. Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Rev Esp Quimioter. 2018;31:110–7.PubMedPubMedCentral
11.
Köves B, Magyar A, Tenke P. Spectrum and antibiotic resistance of catheter-associated urinary tract infections. GMS Infect Dis. 2017;5:Doc06.PubMedPubMedCentral
12.
Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–43.CrossRefPubMed
13.
Hof H. Die unkomplizierte Harnwegsinfektion. Im Blickpunkt: Pivmecillinam und Nitroxolin in der antibiotischen Therapie. Der Gynäkol. 2018;51:581–9.CrossRef
14.
Mareković I, Bošnjak Z, Jurić K, Ćorić M, Popović-Grle S. Susceptibility of Escherichia coli to nitroxoline, an option for uncomplicated urinary tract infections—the first report from Croatia. J Chemother. 2018;30:189–91.CrossRefPubMed
15.
Sobke A, Makarewicz O, Baier M, Bär C, Pfister W, Gatermann SG, Pletz MW, Forstner C. Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline. Int J Antimicrob Agents. 2018;51:213–20.CrossRefPubMed
16.
Sobke A, Klinger M, Hermann B, Sachse S, Nietzsche S, Makarewicz O, Keller PM, Pfister W, Straube E. The urinary antibiotic 5-nitro-8-hydroxyquinoline (nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother. 2012;56:6021–5.CrossRefPubMedPubMedCentral
Metadata
Title
Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria
Authors
Herbert Hof
C. Juretschke
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2019
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1253-y

Other articles of this Issue 3/2019

Infection 3/2019 Go to the issue

Images in Infection

18F-FDG PET/CT monitoring of non-tuberculous mycobacterial infection in a child with interleukin-12 receptor β-1 deficiency

Case Report

Actinomyces spp. bloodstream and deep vein thrombus infections in people who inject drugs

Case Report

Treatment of a broncho-esophageal fistula complicated by severe ARDS

Brief Report

Vertebral osteomyelitis due to Candida species

Original Paper

Analysis of acute respiratory infections due to influenza virus A, B and RSV during an influenza epidemic 2018

Original Paper

Correlation between Streptococcus bovis bacteremia and density of cows in Galicia, northwest of Spain
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits